HNSBF Stock, Hansa Biopharma AB Information

Hansa Biopharma AB is a biopharmaceutical company which develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications.